Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print] Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. Lee AC et al. J…
Early salivary changes in multiple myeloma patients undergoing autologous HSCT.
van Leeuwen S et al. Oral Dis. 2018 Sep. doi: 10.1111/odi.12866
Vos JM et al. J Neurol Neurosurg Psychiatry. 2018 Sep. doi: 10.1136/jnnp-2017-316689.
Calcified Alveolar Septal Pulmonary Amyloidosis as an Initial Manifestation of Multiple Myeloma. Kevorkof GV et al. Arch Bronconeumol. 2018 Mar 5. pii: S0300-2896(18)30020-6. doi: 10.1016/j.arbres.2018.01.005. [Epub ahead of print]. Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bryant AR et al. Bone Marrow Transplant. 2018 Mar 7. doi: 10.1038/s41409-018-0142-4. [Epub ahead of print]. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management,…
Plasma Cell Infiltration of the Kidney as a Manifestation of Myeloma: A Report of Three Cases. Kaur T et al. Indian J Nephrol. 2017 Sep-Oct;27(5):395-398. doi: 10.4103/ijn.IJN_215_16. Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures. Crowley MP et al. Pathol Oncol Res. 2017 Sep 13. doi: 10.1007/s12253-017-0300-9. [Epub ahead of print]. Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid…